0000000000525776

AUTHOR

Pablo E. Pergola

showing 1 related works from this author

Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy:

2021

n/a.

Oncologymedicine.medical_specialtyMEDLINEeGFR declineType 2 diabetesEgfr declineendothelin receptor antagonistlaw.inventionRandomized controlled triallawInternal medicinePost-hoc analysismedicinebusiness.industryEndothelin receptor antagonistAtrasentan22/2 OA procedureGeneral Medicinemedicine.diseaseClinical trialNephrologyrandomized controlled trialtype 2 diabetesbusinesschronic kidney diseasemedicine.drugJournal of the American Society of Nephrology
researchProduct